Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies.

Journal of Biomedical Science
Hsin-An Hou, Hwei-Fang Tien

Abstract

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of clinical features, underlying pathogenesis and treatment outcomes. Recent advances in genomic techniques have unraveled the molecular complexity of AML leukemogenesis, which in turn have led to refinement of risk stratification and personalized therapeutic strategies for patients with AML. Incorporation of prognostic and druggable genetic biomarkers into clinical practice to guide patient-specific treatment is going to be the mainstay in AML therapeutics. Since 2017 there has been an explosion of novel treatment options to tailor personalized therapy for AML patients. In the past 3 years, the U.S. Food and Drug Administration approved a total of eight drugs for the treatment of AML; most specifically target certain gene mutations, biological pathways, or surface antigen. These novel agents are especially beneficial for older patients or those with comorbidities, in whom the treatment choice is limited and the clinical outcome is very poor. How to balance efficacy and toxicity to further improve patient outcome is clinically relevant. In this review article, we give an overview of the most relevant genetic markers in AML with special focus on the ...Continue Reading

References

Jul 1, 1991·The Journal of Experimental Medicine·M OgawaS Nishikawa
Jan 1, 1989·British Journal of Haematology·D ToksozC J Marshall
Jan 15, 1988·International Journal of Cancer. Journal International Du Cancer·H P SennC Moroni
Mar 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·C J FarrC J Marshall
May 23, 1998·Annual Review of Immunology·D T Chao, S J Korsmeyer
Mar 14, 2000·Current Opinion in Cell Biology·G W Reuther, C J Der
Mar 31, 2000·Trends in Cell Biology·J M ShieldsC J Der
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
May 18, 2001·Nature·P Blume-Jensen, T Hunter
Mar 5, 2002·Nature Medicine·Vladimir J N BykovGalina Selivanova
Aug 15, 2002·Blood·D Gary Gilliland, James D Griffin
Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Jan 2, 2003·Nature Reviews. Cancer·Julian Downward
Aug 6, 2003·British Journal of Haematology·Panagiotis D KottaridisDavid C Linch
Dec 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Todd M ZimmermanThomas F Gajewski
Apr 27, 2005·Cell·Yuki OkadaYi Zhang
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanUNKNOWN Cancer and Leukemia Group B
Jun 23, 2007·Nature Reviews. Drug Discovery·Panagiotis A KonstantinopoulosAthanasios G Papavassiliou
Oct 25, 2007·Nature Reviews. Cancer·Andrei V Krivtsov, Scott A Armstrong
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas NeubauerClara D Bloomfield
Sep 24, 2009·Nature Reviews. Molecular Cell Biology·Mo Chen, James L Manley
Nov 26, 2009·Nature·Lenny DangShinsan M Su

❮ Previous
Next ❯

Citations

Sep 17, 2020·Journal of Clinical Medicine·Salihanur DariciXu Huang
Apr 4, 2021·Cancers·Lisa Maria MustachioJason Roszik
Apr 4, 2021·Pharmacology & Therapeutics·Mohammed F AlmataniHouda Alachkar
Apr 1, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Iryna KolosenkoCaroline Palm-Apergi

❮ Previous
Next ❯

Methods Mentioned

BETA
sumoylation
ubiquitination
MDS
xenograft

Clinical Trials Mentioned

NCT02421939
NCT03072043
NCT03745716
NCT01915498
NCT02577406
NCT02632708
NCT03515512
NCT03683433
NCT02074839
NCT01757535

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.